Address
304 North Cardinal
St. Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM

$89.00
| Brand | LumiMeds |
| Product | GLP-1 Weight Loss Plan |
| Type | Prescription Telehealth Weight Management Program |
| Form | Subcutaneous Injectable Solution (Vial & Syringe / Pen Dispenser based on state availability) |
| Quantity | 30-Day Supply per shipment (includes medication vials, sterile syringes, and alcohol prep wipes) |
| Active Ingredients | Semaglutide (GLP-1 receptor agonist) or Tirzepatide (GIP/GLP-1 dual receptor agonist), depending on clinical eligibility and prescription |
| Suggested Use | Administer subcutaneously once weekly into the abdomen, thigh, or upper arm as directed by a licensed medical provider |
| Manufacturer | Dispensed through licensed, regulated 503A / 503B U.S. compounding pharmacies partnered with LumiMeds |
| Country of Origin | United States |
The LumiMeds GLP-1 Weight Loss Program is a comprehensive telehealth service formulated to make prescription-grade metabolic care accessible, safe, and transparent. Instead of navigating insurance hurdles or retail pharmacy backorders, eligible patients receive direct clinical consultations, personalized treatment plans, and doctor-prescribed GLP-1 medications mailed straight to their home.
Glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) dual agonists represent the gold standard in contemporary clinical obesity medicine. LumiMeds bridges clinical evaluation with ongoing support, ensuring each patient starts at an appropriate introductory dose and titrates safely under continuous medical direction.
Appetite & Satiety Regulation: Helps reduce persistent hunger signals (“food noise”) by mimicking natural satiety hormones produced in the gastrointestinal tract.
Sustained Caloric Deficit Support: Slows gastric emptying, allowing individuals to feel satisfied with smaller, nutrient-dense portions throughout the day.
Metabolic & Blood Glucose Support: Helps improve post-meal insulin release and assists in maintaining balanced blood sugar levels already within normal ranges.
Personalized Dose Titration: Medical providers adjust dosage gradually over several months, minimizing common gastrointestinal side effects while optimizing tolerability.
Convenient Home Delivery: Eliminates wait times and retail pharmacy inventory shortages with automated monthly refills and insulated packaging.
Each LumiMeds treatment plan is compounded and dispensed according to an individual prescription written by a licensed healthcare provider:
Compounded Semaglutide: A GLP-1 receptor agonist that targets brain receptors regulating appetite, slowing stomach emptying to promote feelings of fullness.
Compounded Tirzepatide: A dual GIP and GLP-1 receptor agonist that targets both gut hormone pathways for dual metabolic signaling.
Inactive / Excipient Ingredients: Sterile water for injection, buffering agents (such as dibasic sodium phosphate), and antimicrobial preservatives (such as benzyl alcohol or phenol) depending on specific compounding pharmacy formulation. Some formulations may incorporate Vitamin B12 (cyanocobalamin) or L-carnitine as compound adjuncts to support cellular energy.
Ancillary Medical Supplies: U-100 sterile insulin syringes, 31G safety needles, and 70% isopropyl alcohol prep pads.
GLP-1 is a natural incretin hormone secreted by the L-cells of the intestines in response to nutrient intake. It signals the brain’s hypothalamus to downregulate appetite and stimulate satiety. Simultaneously, it delays gastric motility, meaning food remains in the stomach longer, physically extending postprandial fullness.
LumiMeds provides access to medications that mimic these exact hormonal signals. By binding to GLP-1 (and GIP in the case of Tirzepatide) receptors with extended biological half-lives, the once-weekly medication provides continuous metabolic support. When paired with a caloric deficit, adequate dietary protein, hydration, and regular resistance exercise, this mechanism supports progressive, clinically meaningful weight loss.
Frequency: Administer once every 7 days, on the same day each week.
Timing: Can be taken at any time of day, with or without food.
Administration Route: Subcutaneous injection only. Rotate injection sites weekly between the lower abdomen (at least 2 inches away from the navel), front of the middle thighs, or outer back of the upper arm.
Dose Escalation: Always follow your provider’s precise titration schedule. Typical protocols start at the lowest introductory dose (e.g., 0.25 mg weekly for Semaglutide or 2.5 mg weekly for Tirzepatide) for 4 weeks before evaluating dosage progression. Never self-increase doses without provider authorization.
Storage Instructions: Store unopened and in-use vials in the refrigerator between 36°F and 46°F (2°C to 8°C). Do not freeze. Protect medication from excessive heat and direct sunlight. Safely discard used needles in a heavy-duty plastic puncture-resistant sharps container.
This program is intended for adults aged 18 and older who meet standard clinical criteria for medical weight management:
Individuals with a Body Mass Index (BMI) of 30 or greater.
Individuals with a BMI of 27 or greater with one or more weight-related comorbidities (such as hypertension, dyslipidemia, or insulin resistance).
Adults who have experienced difficulty achieving sustained weight loss through traditional diet and physical exercise alone.
Patients seeking a guided, medically monitored telehealth alternative to retail pharmacy visits.
Do not use GLP-1 medications if you:
Have a personal or family history of Medullary Thyroid Carcinoma (MTC).
Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Have a known hypersensitivity or severe allergic reaction to Semaglutide, Tirzepatide, or any inactive ingredients in the formulation.
Are currently pregnant, planning to become pregnant within the next two months, or breastfeeding.
Have a history of pancreatitis or severe gastrointestinal disease (including severe gastroparesis).
Have Type 1 diabetes or a history of diabetic ketoacidosis.
Prescription Required: LumiMeds GLP-1 treatments are medical therapies requiring an online clinical questionnaire and provider review. Submitting an order does not guarantee a prescription; treatment approval is solely at the medical provider’s clinical discretion.
Common Side Effects: Gastrointestinal symptoms are the most commonly reported, including mild-to-moderate nausea, constipation, diarrhea, bloating, belching, heartburn, and transient fatigue. These typically peak during dose escalation and decrease over time.
Hydration & Nutrition: Adequate fluid intake (at least 64–80 oz of water daily) and sufficient protein consumption (0.8–1.0 g per pound of ideal body weight) are strongly recommended to support lean muscle preservation and prevent dehydration-induced constipation.
Compounded Medication Disclosure: Compounded drugs are prepared pursuant to a valid prescription from state-licensed compounding facilities. They are not independently reviewed or approved by the FDA for safety, effectiveness, or quality, but are compounded in compliance with federal section 503A/503B regulatory standards.
Zero Pharmacy Lines or Backorders: Medication is dispensed directly from certified partner facilities and delivered straight to your residence, bypassing retail inventory shortages.
Structured Clinical Titration: Every shipment aligns with medical safety protocols designed to minimize side effects and optimize long-term adherence.
Holistic Protocol: The plan delivers complete supply sets (needles, wipes, clear instructional guides) with temperature-monitored packaging to ensure product integrity upon arrival.
Ongoing Clinical Check-Ins: Access to telehealth support means you can ask dosage questions, report symptoms, and adjust your treatment without paying separate office co-pays.
What is the LumiMeds GLP-1 Weight Loss Program?
It is a direct-to-consumer medical weight loss service that connects patients with licensed healthcare professionals to evaluate, prescribe, and deliver GLP-1 medications (such as compounded Semaglutide or Tirzepatide) directly to their door.
Do I need an existing prescription from my local doctor?
No. Your initial health history and eligibility are reviewed online by a licensed telehealth provider affiliated with LumiMeds. If deemed clinically appropriate, the provider writes and issues your prescription directly.
How do I administer the medication?
The medication is administered once per week using a tiny, ultra-fine subcutaneous needle into the fatty tissue of your abdomen, thigh, or upper arm. Detailed step-by-step injection guidelines and all required medical supplies are included with your kit.
How long will it take to see results?
Because treatment begins at a low titration dose to ensure gastrointestinal tolerance, metabolic adaptation varies per individual. Most patients note changes in appetite and portion control within the first 2 to 4 weeks, with progressive weight loss continuing alongside healthy lifestyle habits.
What happens if I miss a weekly dose?
If you miss a dose and your next scheduled dose is more than 48 hours away, administer the missed dose as soon as you remember. If your next dose is less than 48 hours away, skip the missed dose and resume your regular weekly schedule. Never take two doses within 48 hours of each other.
How should I store my medication when it arrives?
Upon unboxing, immediately place your medication vial in the refrigerator at 36°F to 46°F (2°C to 8°C). Keep it away from the freezer compartment, and ensure it is kept away from direct sunlight.
The LumiMeds GLP-1 Weight Loss Program delivers a streamlined, medically supervised pathway to modern metabolic management. By pairing licensed clinical guidance, dependable cold-chain home delivery, and proven GLP-1/GIP receptor agonist options, it offers an accessible, transparent, and patient-centered solution for long-term weight health.




